Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36. Following the transaction, the chief operating officer now owns 67,109 shares in the company, valued at approximately $7,391,385.26. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.91, for a total value of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $115.63 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock’s fifty day moving average is $95.28 and its 200 day moving average is $95.48. The firm has a market capitalization of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61. Blueprint Medicines Co. has a fifty-two week low of $72.24 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s revenue was up 126.5% on a year-over-year basis. During the same quarter last year, the business earned ($2.20) EPS. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BPMC shares. Wedbush reaffirmed an “outperform” rating and set a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $122.72.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BPMC. Quarry LP purchased a new stake in shares of Blueprint Medicines in the third quarter worth approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the 4th quarter valued at $51,000. Covestor Ltd increased its stake in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares during the period. Quantbot Technologies LP bought a new stake in shares of Blueprint Medicines during the third quarter worth $108,000. Finally, Values First Advisors Inc. purchased a new stake in shares of Blueprint Medicines during the third quarter valued at $122,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.